MedTrace Logo

Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma

NCT03614546 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2019-01-23

No results posted yet for this study

Summary

The subjects of primary hepatocellular carcinoma diagnosed pathologically or clinically will be grouped according to the size, location, number and function of the liver, and respectively received Intensity-modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT), Transarterial chemoembolization (TACE) or surgery.

Conditions

  • Primary Hepatocellular Carcinoma

Interventions

RADIATION

SBRT

Stereotactic Body Radiation Therapy (SBRT)

RADIATION

IMRT

Intensity-modulated Radiation Therapy (IMRT)

PROCEDURE

Hepatectomy

Hepatectomy

PROCEDURE

TACE

transarterial chemoembolization (TACE)

Sponsors & Collaborators

  • The Third Xiangya Hospital of Central South University

    lead OTHER

Principal Investigators

  • peiguo cao, doctor · The Third Xiangya Hospital, Central South University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-10
Primary Completion
2020-07-30
Completion
2021-07-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03614546 on ClinicalTrials.gov